Hologic, Inc. (NASDAQ:HOLX) Shares Acquired by Two Sigma Advisers LP

Two Sigma Advisers LP boosted its holdings in Hologic, Inc. (NASDAQ:HOLX - Free Report) by 78.2% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 31,000 shares of the medical equipment provider's stock after acquiring an additional 13,600 shares during the period. Two Sigma Advisers LP's holdings in Hologic were worth $2,235,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds have also recently added to or reduced their stakes in HOLX. Principal Financial Group Inc. raised its holdings in shares of Hologic by 0.6% in the fourth quarter. Principal Financial Group Inc. now owns 271,152 shares of the medical equipment provider's stock worth $19,547,000 after acquiring an additional 1,606 shares during the last quarter. Groupama Asset Managment increased its position in Hologic by 63.4% during the 4th quarter. Groupama Asset Managment now owns 54,214 shares of the medical equipment provider's stock worth $3,918,000 after purchasing an additional 21,037 shares in the last quarter. Proficio Capital Partners LLC acquired a new position in Hologic in the 4th quarter valued at about $4,215,000. Signaturefd LLC lifted its holdings in Hologic by 34.5% in the 4th quarter. Signaturefd LLC now owns 2,940 shares of the medical equipment provider's stock valued at $212,000 after purchasing an additional 754 shares in the last quarter. Finally, Brevan Howard Capital Management LP boosted its stake in shares of Hologic by 85.5% during the 4th quarter. Brevan Howard Capital Management LP now owns 19,436 shares of the medical equipment provider's stock worth $1,401,000 after purchasing an additional 8,960 shares during the last quarter. 94.73% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

HOLX has been the subject of a number of analyst reports. Leerink Partnrs lowered shares of Hologic from a "strong-buy" rating to a "hold" rating in a research report on Thursday, February 6th. Wall Street Zen downgraded Hologic from a "buy" rating to a "hold" rating in a report on Monday, May 5th. Evercore ISI decreased their price objective on Hologic from $65.00 to $62.00 and set an "in-line" rating on the stock in a report on Friday, May 2nd. Morgan Stanley dropped their target price on Hologic from $77.00 to $65.00 and set an "equal weight" rating for the company in a research note on Monday, May 5th. Finally, Argus downgraded Hologic from a "buy" rating to a "hold" rating in a research report on Monday, March 3rd. Twelve investment analysts have rated the stock with a hold rating, five have issued a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat, Hologic has an average rating of "Hold" and a consensus price target of $77.42.

Insider Buying and Selling at Hologic

In other news, Director Martin D. Madaus acquired 5,445 shares of the business's stock in a transaction on Wednesday, May 7th. The shares were purchased at an average price of $55.24 per share, for a total transaction of $300,781.80. Following the acquisition, the director now directly owns 5,445 shares of the company's stock, valued at $300,781.80. This represents a ∞ increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. 1.88% of the stock is owned by corporate insiders.

Hologic Stock Down 0.3%

Shares of NASDAQ:HOLX traded down $0.16 during midday trading on Monday, hitting $62.01. 2,584,438 shares of the company's stock traded hands, compared to its average volume of 2,269,862. The firm's fifty day moving average price is $58.15 and its two-hundred day moving average price is $65.69. The company has a debt-to-equity ratio of 0.52, a quick ratio of 2.78 and a current ratio of 3.49. Hologic, Inc. has a twelve month low of $51.90 and a twelve month high of $84.67. The company has a market cap of $13.82 billion, a PE ratio of 19.56, a P/E/G ratio of 2.14 and a beta of 0.54.

Hologic (NASDAQ:HOLX - Get Free Report) last issued its quarterly earnings data on Thursday, May 1st. The medical equipment provider reported $1.03 EPS for the quarter, topping analysts' consensus estimates of $1.02 by $0.01. Hologic had a return on equity of 19.72% and a net margin of 18.42%. The company had revenue of $1.01 billion for the quarter, compared to analysts' expectations of $1 billion. During the same quarter in the previous year, the firm posted $1.03 earnings per share. The firm's quarterly revenue was down 1.2% on a year-over-year basis. On average, equities research analysts anticipate that Hologic, Inc. will post 4.28 EPS for the current fiscal year.

Hologic Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.